Last reviewed 2026-04-23 · How we verify

HR-1703

HR-1703 is a tyrosine kinase inhibitor that targets specific oncogenic pathways to inhibit tumor cell growth and proliferation.

HR-1703 is a tyrosine kinase inhibitor that targets specific oncogenic pathways to inhibit tumor cell growth and proliferation. Used for Cancer (specific indication under phase 3 evaluation not publicly detailed).

At a glance

Mechanism of action

HR-1703 is a small-molecule kinase inhibitor developed by Guangdong Hengrui Pharmaceutical. While the precise molecular targets have not been widely disclosed in public literature, it is being evaluated in phase 3 clinical trials for cancer indications. The drug likely works by inhibiting one or more receptor tyrosine kinases or intracellular signaling proteins critical to tumor survival.

Approved indications

• Cancer (specific indication under phase 3 evaluation not publicly detailed)

Common side effects

No common side effects on file.

Key clinical trials

• A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.